palbociclib,Fulvestrant,Avelumab
pfizer,medsir,Merck
['palbociclib', 'palbo', 'palmira']
consistent with the pace trial, the palmira randomized phase 2 trial showed no benefit in terms of pfs or os with the use of palbociclib beyond progression to 1l et+palbo. patients progressing on 1l palbo should not receive further exposure to palbo. #asco23 
Medical Oncologist, Research Fellow @DanaFarber | @Harvard | PhD @LaStatale | former @IEOufficiale. Interested in breast oncology, HER2, ADCs & good music.